Impact of BCL-2 Expression on Course of Disease in Neuroblastoma

Abstract

Objective The antiapoptotic BCL-2 protein has implications for maturation and differentiation of neural tissue and acts as a strong modulator of carcinogenesis in different tumors. Recent research focuses not only on its benefit as a prognostic factor, but also as a potential therapeutic target. The role of BCL-2 in neuroblastoma, the most common extracranial solid tumor in childhood, remains controversial. The aim of our study was to determine the gene expression level of BCL-2 in a large cohort of neuroblastoma patients and its correlation with clinical parameters.

Methods Tumor samples and clinical data were collected from 100 neuroblastoma patients treated according to the NB2004 protocol of the German Society of Pediatric Oncology and Hematology. BCL-2 gene expression levels were measured by quantitative reverse transcription polymerase chain reaction and correlated with clinical parameters.

Results BCL-2 expression was detected in all tumor samples. Relative BCL-2 expression levels were higher in females versus males (1.839 vs. 1.342; p = 0.0143), in patients with low versus high International Neuroblastoma Staging System stage (2.051 vs. 1.463; p = 0.0206), in nonmetastatic versus metastatic disease (1.801 vs. 1.342; p = 0.0242), as well as in patients without presurgical chemotherapy (2.145 vs. 1.402; p = 0.0016), but was not associated with overall survival and MYCN amplification.

Conclusion Our study demonstrates the ubiquitous expression of BCL-2 in neuroblastoma and suggests the possibility for targeted therapy with BCL-2 inhibitors, even in lower-stage neuroblastoma. It also underlines the need for further research on concomitant genetic alterations for a better understanding of the impact of BCL-2 on this pediatric tumor type.

Keywords

neuroblastoma - genetic alterations - BCL-2 - targeted therapy - gene expression

Publikationsverlauf

Eingereicht: 05. Mai 2023

Angenommen: 15. August 2023

Artikel online veröffentlicht:
29. September 2023

• References

• 1 Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362 (23) 2202-2211
• 2 Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Påhlman S. A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. Lab Invest 1996; 75 (05) 659-675
• 3 London WB, Castleberry RP, Matthay KK. et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23 (27) 6459-6465
• 4 Brodeur GM. Spontaneous regression of neuroblastoma. Cell Tissue Res 2018; 372 (02) 277-286
• 5 Berthold F, Spix C, Kaatsch P, Lampert F. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979-2015. Paediatr Drugs 2017; 19 (06) 577-593
• 6 Zafar A, Wang W, Liu G. et al. Molecular targeting therapies for neuroblastoma: progress and challenges. Med Res Rev 2021; 41 (02) 961-1021
• 7 Schwab M. Amplification of N-myc as a prognostic marker for patients with neuroblastoma. Semin Cancer Biol 1993; 4 (01) 13-18
• 8 Brodeur GM, Azar C, Brother M. et al. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer 1992; 70 (6, Suppl): 1685-1694
• 9 Liu Z, Chen SS, Clarke S, Veschi V, Thiele CJ. Targeting MYCN in pediatric and adult cancers. Front Oncol 2021; 10: 623679
• 10 Shamas-Din A, Kale J, Leber B, Andrews DW. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol 2013; 5 (04) a008714
• 11 Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22 (53) 8590-8607
• 12 Leber B, Lin J, Andrews DW. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 2007; 12 (05) 897-911
• 13 Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11 (09) 621-632
• 14 Kalkavan H, Green DR. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ 2018; 25 (01) 46-55
• 15 Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007; 19 (05) 488-496
• 16 Pegoraro L, Palumbo A, Erikson J. et al. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci U S A 1984; 81 (22) 7166-7170
• 17 Li S, Lin P, Young KH, Kanagal-Shamanna R, Yin CC, Medeiros LJ. MYC/BCL2 double-hit high-grade B-cell lymphoma. Adv Anat Pathol 2013; 20 (05) 315-326
• 18 Kim JY, Kim J, Bazarsad S, Cha IH, Cho SW, Kim J. Bcl-2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas. Oral Dis 2019; 25 (04) 1158-1168
• 19 Renouf DJ, Wood-Baker R, Ionescu DN. et al. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. J Thorac Oncol 2009; 4 (04) 486-491
• 20 Gioacchini FM, Alicandri-Ciufelli M, Rubini C, Magliulo G, Re M. Prognostic value of Bcl-2 expression in squamous cell carcinoma of the larynx: a systematic review. Int J Biol Markers 2015; 30 (02) e155-e160
• 21 Kim JW, Kong IG, Lee CH. et al. Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival. Otolaryngol Head Neck Surg 2008; 139 (05) 708-712
• 22 Diensthuber M, Potinius M, Rodt T. et al. Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma. J Neurooncol 2008; 89 (02) 131-139
• 23 Reed JC, Meister L, Tanaka S. et al. Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 1991; 51 (24) 6529-6538
• 24 Bierbrauer A, Jacob M, Vogler M, Fulda S. A direct comparison of selective BH3-mimetics reveals BCL-X_L, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. Br J Cancer 2020; 122 (10) 1544-1551
• 25 Van Goethem A, Yigit N, Moreno-Smith M. et al. Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma. Oncotarget 2017; 8 (34) 57047-57057
• 26 Klenke S, Akdeli N, Stelmach P, Heukamp L, Schulte JH, Bachmann HS. The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines. BMC Cancer 2019; 19 (01) 243
• 27 Berthold F. NB2004 Trial Protocol for Risk Adapted Treatment of Children with Neuroblastoma. Children's Hospital, University of Cologne; Kerpener Str. 62; D-50924 Köln, Germany; 2004:264
• 28 Brodeur GM, Pritchard J, Berthold F. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11 (08) 1466-1477
• 29 Brodeur GM, Seeger RC, Barrett A. et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6 (12) 1874-1881
• 30 Fischer M, Spitz R, Oberthür A, Westermann F, Berthold F. Risk estimation of neuroblastoma patients using molecular markers. Klin Padiatr 2008; 220 (03) 137-146
• 31 Temple WC, Vo KT, Matthay KK. et al. Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma. Cancer Med 2021; 10 (07) 2232-2241
• 32 Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29 (09) e45
• 33 Mühling J, Eberherr C, Müller Höcker J. et al. Vessel adherent growth represents a major challenge in the surgical resection of neuroblastoma and is associated with adverse outcome. J Pediatr Surg 2019; 54 (11) 2336-2342
• 34 Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228 (4706): 1440-1443
• 35 Zhang KZ, Westberg JA, Hölttä E, Andersson LC. BCL2 regulates neural differentiation. Proc Natl Acad Sci U S A 1996; 93 (09) 4504-4508
• 36 Zhou JD, Zhang TJ, Xu ZJ. et al. BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia. Diagn Pathol 2019; 14 (01) 68
• 37 Goldsmith KC, Gross M, Peirce S. et al. Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res 2012; 72 (10) 2565-2577
• 38 Matthay KK, Maris JM, Schleiermacher G. et al. Neuroblastoma. Nat Rev Dis Primers 2016; 2: 16078
• 39 Weinreb M, Day PJ, Niggli F, Raafat F, Mann JR. BCL-2 oncoprotein in neuroblastoma. Lancet 1995; 345 (8955): 992-993
• 40 Beierle EA, Dai W, Iyengar R, Langham Jr MR, Copeland III EM, Chen MK. Differential expression of Bcl-2 and Bax may enhance neuroblastoma survival. J Pediatr Surg 2003; 38 (03) 486-491
• 41 Lamers F, Schild L, den Hartog IJ. et al. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. Eur J Cancer 2012; 48 (16) 3093-3103
• 42 Pfluger T, Schmied C, Porn U. et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol 2003; 181 (04) 1115-1124
• 43 Lasorella A, Iavarone A, Israel MA. Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Res 1995; 55 (20) 4711-4716
• 44 Mejía C, Navarro S, Llombart-Bosch A. Apoptosis in peripheral neuroblastic tumors. Immunohistochemical expression of bcl-2 and p53 is related to DNA fragmentation. Histol Histopathol 2007; 22 (12) 1365-1370
• 45 Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nuñez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 1993; 143 (06) 1543-1550
• 46 Jacobs JF, van Bokhoven H, van Leeuwen FN. et al. Regulation of MYCN expression in human neuroblastoma cells. BMC Cancer 2009; 9: 239
• 47 Lestini BJ, Goldsmith KC, Fluchel MN. et al. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009; 8 (16) 1587-1595
• 48 Dole M, Nuñez G, Merchant AK. et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994; 54 (12) 3253-3259
• 49 Bouchalova K, Kharaishvili G, Bouchal J, Vrbkova J, Megova M, Hlobilkova A. Triple negative breast cancer - BCL2 in prognosis and prediction. Review. Curr Drug Targets 2014; 15 (12) 1166-1175
• 50 Feng C, Wu J, Yang F. et al. Expression of Bcl-2 is a favorable prognostic biomarker in lung squamous cell carcinoma. Oncol Lett 2018; 15 (05) 6925-6930
• 51 Berthold F. Neuroblastomstudie NB97. Gesellschaft für pädiatrische Onkologire und Hämatologie; 2002: 148
• 52 Fang J, Gu L, Zhu N, Tang H, Alvarado CS, Zhou M. Tissue factor/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells. BMC Cancer 2008; 8: 69
• 53 Ekmekci S, Olgun N, Özer E. The relationship between apoptotic activity and prognostic factors in neuroblastomas. Turk Patoloji Derg 2016; 32 (02) 99-104
• 54 Hwang HS, Sung HJ, Kim MJ. et al. Extra copy number of BCL2 is correlated with increased BCL-2 protein expression and poor survival in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Leuk Lymphoma 2022; 63 (13) 3072-3081
• 55 Akao Y, Otsuki Y, Kataoka S, Ito Y, Tsujimoto Y. Multiple subcellular localization of bcl-2: detection in nuclear outer membrane, endoplasmic reticulum membrane, and mitochondrial membranes. Cancer Res 1994; 54 (09) 2468-2471
• 56 Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993; 53 (19) 4701-4714
• 57 Dalton KM, Krytska K, Lochmann TL. et al. Venetoclax-based rational combinations are effective in models of MYCN-amplified neuroblastoma. Mol Cancer Ther 2021; 20 (08) 1400-1411